About Us       Blog       Clients       Disclaimer       Market Basics       Partners       Quotes & News       Video       Contact Us
The QualityStocks Daily Newsletter for Tuesday, October 8th, 2013

The QualityStocks
Daily Stock List


Guardian 8 Holdings (GRDH)

Zacks reported recently on Guardian 8 Holdings (GRDH), OTCPicks did earlier, and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Guardian 8 Holdings, through Guardian 8 Corporation, develops and manufactures personal security devices. Guardian 8 Corporation is the wholly owned operating subsidiary of Guardian 8 Holdings. Guardian 8 develops, manufactures, and sells innovative personal security devices designed to deliver layered defense for low-impact de-escalation and risk mitigation. Guardian 8 is based in Scottsdale, Arizona.

In March 2013, Guardian 8 launched their maiden product, the G8 ProV2. This is the first in a new category of security products called enhanced non-lethals (ENL). G8 ProV2 protects individuals from aggressors and assailants, while notifying law enforcement authorities and other stakeholders of the situation. Enhanced Non-Lethal Devices are a category of personal security products that incorporate layered defensive measures to help security professionals and consumers protect themselves against personal attacks, while capturing critical images to defend against personal liability.

The G8 ProV2’s inherent risk mitigation capabilities are additionally enhanced through use of a Bluetooth® driven Command Center Communication Link and Incident Recording Capabilities. Guardian 8 markets their personal defense solutions to professional security organizations and individuals and families via distributors in the U.S. and worldwide.

Guardian 8 provides Training & Certification for the G8 ProV2. The Company is scheduling training opportunities across the nation throughout the remainder of 2013. They indicate that hands-on certification is essential for properly integrating the G8 ProV2 within an organization.

Yesterday, Guardian 8 Corporation, a provider of enhanced non-lethal [ENL] personal defense devices, announced that they will be increasing the re-supply of their Pro V2 inventory following a successful industry conference in Chicago, Illinois. The ASIS conference is held each year and represents the largest conference of its type for the security industry.

The G8 ProV2 fully integrates a number of non-lethal technologies and a communications platform to provide a safer personal defense solution. It provides the aforementioned layered defense. This includes a red laser spotter, siren, strobe light, O. C. pepper spray, camera with voice, and video auto-record functionality, push-to-talk communications capabilities.

Guardian 8 Holdings (GRDH), closed Tuesday's trading session at $0.6002, up 25.04%, on 150,895 volume with 41 trades. The average volume for the last 60 days is 18,169 and the stock's 52-week low/high is $0.10/$0.55.

Nutranomics, Inc. (NNRX)

Pumps and Dumps and PennyStocks24 reported today on Nutranomics, Inc. (NNRX), PennyOmega, Real Pennies, Global Equity Alert, and PennyStocks Forever did earlier, and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.

Founded in 1995 by Dr. Tracy K. Gibbs, Nutranomics, Inc. involves in the research and development of nutritional food products. The Company produced and branded their own product line in 1997, and started to sell to retail outlets as well as to the public. Nutranomics' mission is to increase human health and longevity by way of education and self-awareness. The Company’s shares trade on the OTC Bulletin Board. Nutranomics has their headquarters in Draper, Utah.

In addition, Nutranomics has produced formulas for hundreds of other companies.  The Company has sales representatives throughout the United States, Canada, Taiwan, Japan, Singapore, Philippines, Malaysia, and Korea.

Last week, Nutranomics announced that the results of human patient clinical studies undertaken by the Company concerning Glucozyme™ are nearing a public release date.  Glucozyme™ is a proprietary nutritional supplement undergoing development by Nutranomics. Glucozyme™ has been shown to assist in the processing of sugars to maintain proper glucose and insulin levels in patients with diabetes and pre-diabetes.

Following the conclusion of the latest Glucozyme™ clinical studies conducted in Japan and Mexico, the resulting new patient data was compiled and compared with previous testing conducted in North America before submission for product approval and distribution in a number of global markets. Nutranomics’ anticipation is that data compilation and analysis from the Glucozyme™ clinical studies will be made available within the next two to three weeks.

Today, Nutranomics announced that because of a rapid increase in demand for the Company’s products in the southwest United States, they have hired Monae Byrne as their new territory manager for the States of Colorado, New Mexico, and Wyoming.

Dr. Tracy K. Gibbs, Chief Executive Officer of Nutranomics, stated, "Monae was previously one of the leading sales reps for one of Nutranomics' main competitors, Garden of Life, and has vast experience with the natural whole food products marketplace into which we are currently undergoing a rapid expansion."

Nutranomics, Inc. (NNRX), closed Tuesday's trading session at $0.40, up 2.56%, on 285,590 volume with 98 trades. The average volume for the last 60 days is 645,261 and the stock's 52-week low/high is $0.12/$1.48.

Aethlon Medical, Inc. (AEMD)

PennyStocks24, Pennybuster, RedChip, and Investor Ideas reported earlier on Aethlon Medical, Inc. (AEMD), and we report on the Company today, here at the QualityStocks Daily Newsletter.

Aethlon Medical, Inc.'s mission is to create novel medical devices that address unmet medical needs in cancer, infectious disease, and other life-threatening conditions. Their Aethlon ADAPT™ System (Adaptive Dialysis-Like Affinity Platform Technology) is a revenue-stage technology platform. This system provides the basis for a new class of therapeutics that target the selective removal of disease enabling particles from the entire circulatory system.

The Aethlon ADAPT™ System is a medical device platform that joins single or multiple affinity drug agents with advanced plasma membrane technology. This is to create therapeutic filtration devices that selectively remove harmful particles from the entire circulatory system without the loss of essential blood components.

The Aethlon ADAPT™ product pipeline includes the Aethlon Hemopurifier® to address infectious disease and cancer. Aethlon is currently preparing to launch the first U.S. studies of the Hemopurifier® as a therapy to address hepatitis c virus (HCV) based on the recent approval of an Investigational Device Exemption (IDE) by the United States Food and Drug Administration (FDA). Aethlon Medical’s Aethlon Hemopurifier® is a first-in-class medical device with broad-spectrum capabilities against viral pathogens. These include the human immunodeficiency virus (HIV), hepatitis C virus (HCV), and numerous bioterror and pandemic threats. 

Their pipeline also includes a medical device undergoing development under a five-year contract with Defense Advanced Research Projects Agency (DARPA) to reduce the incidence of sepsis in combat-injured soldiers (DARPA Sepsis Program). Moreover, the Company has their HER2osome™. It provides a therapeutic strategy to maximize the ability of the immune system and established drug therapies to combat HER2+ breast cancer.

Aethlon also has their ELLSA™ Exosome Assay. This is an enzyme-linked lectin-specific assay that has demonstrated the ability to identify and quantify the presence of exosomes underlying the human immunodeficiency virus (HIV), tuberculosis (TB), and all forms of cancer tested to date.

In September, Aethlon Medical announced the formal launch of Exosome Sciences, Inc. (ESI), a wholly-owned subsidiary earlier established by Aethlon to pursue exosome-based strategies to diagnose and monitor the progression of cancer, infectious disease, as well as other life-threatening conditions.

Aethlon Medical also announced last month that the Defense Advanced Research Projects Agency (DARPA) exercised an option agreement to proceed with year-three of a five-year $6.8 million contract that was awarded to Aethlon on September 30, 2011 under DARPA's Dialysis-Like Therapeutics (DLT) program.

Aethlon Medical, Inc. (AEMD), closed Tuesday's trading session at $0.1645, up 2.81%, on 111,080 volume with 14 trades. The average volume for the last 60 days is 568,067 and the stock's 52-week low/high is $0.06/$0.293.

DNA Precious Metals, Inc. (DNAP)

Pumps and Dumps, Ascending Stocks, Penny Investor Network, Value Penny Stocks, HoleinOneStocks.net, and HotStockProfits reported today on DNA Precious Metals, Inc. (DNAP), PSNO.ORG, PennyStocks24, SmallCapVoice did earlier, and we are highlighting the Company, here at the QualityStocks Daily Newsletter.

DNA Precious Metals, Inc. is concentrating on near term production of the Montauban tailings mine in Quebec, with an aggressive search for economic production assets. In June of 2011, the Company completed the first acquisition of their Montauban exploration properties in Portneuf County, Quebec, based on a report estimating an historical resource of 47,198 ounces of gold and 480,998 ounces of silver on the Montauban Project. The resource totals are in reference to a section of the gold bearing surface ore over a distance of approximately 600 meters in length.

Engineering Geologist Yves Gagnon’s (a “qualified person” as required by rule 43-101) January 2011 National Instrument 43-101 Technical Report on the Resource Evaluation of the Montauban Tailings states the actual market value of the Montauban Tailings to be a minimum $32 million with the potential of increasing this value with the mica (phlogopite). The basis of this report was on the total measured resources of approximately 428,000 metric tonnes of tailings. Assorted official government documents estimates the total amount of tailings located on the Montauban Mine Property to be over two million metric tonnes.

The Montauban Project is a series of advanced exploration claims. The project is approximately 120 km west of Quebec City and approximately 60 km north of Trois-Rivieres. As of March of this year, DNA Precious Metals has the final plans of the mill for the extraction process of the industrial and precious metals. The Company has completed construction of all access roads to and from the new milling facility.

Yesterday, DNA Precious Metals announced that at the Meeting of the Board of Directors on August 12, 2013, they appointed G.E. (Ted) Creber, QC, and Garfield (Gary) J. Last to join Ronald K. Mann on the Board of Directors. With this addition, the DNA Board has two independent directors. Mr. Creber was the President/Chief Executive Officer of Consumers Gas Company (n/k/a Enbridge). Mr. Last is the President of Mind and Management Corporation, Turks & Caicos, BWI.

DNA Precious Metals, Inc. (DNAP), closed Tuesday's trading session at $0.585, up 21.88%, on 136,391 volume with 65 trades. The average volume for the last 60 days is 4,337 and the stock's 52-week low/high is $0.27/$0.6499.

Premiere Opportunities Group, Inc. (PPBL)

PennyStocks24 reported recently on Premiere Opportunities Group, Inc. (PPBL), SizzlingStockPicks, Wallstreetlivechat did earlier, and we report on the Company, here at the QualityStocks Daily Newsletter.

Based in Totowa, New Jersey, Premiere Opportunities Group, Inc. is presently concentrating their efforts in the apparel industry for women and men's clothing. The Company is additionally working to establish a retail base of stores overseas in Korea and the People’s Republic of China (PRC). This is either through direct ownership or through joint ventures (JVs) for distribution into the Southeast Asian and Mainland China markets.

Premiere Opportunities Group shares trade on the OTC Markets’ OTCQB. Founded in 2004, the Company previously went by the name Premiere Publishing Group, Inc. They changed their name to Premiere Opportunities Group, Inc. in June of 2011.

Premiere Opportunities Group previously announced that they formed a JV with Cabe Studio, LLC.  Cabe Studio will be providing the JV with design, fitting, as well as manufacturing expertise. Premiere, via their apparel division, will supply the expertise in distributing the Cabe line into Southeast Asia and China.

Premiere has a distinctive revenue sharing relationship with Lotte and Hyundai Department stores. This permits the Company to exist in the two most prestigious department store environments in all of Southeast Asia and China.

In September, Premiere Opportunities Group announced that, through their JV with Cabe Studio, they received an order worth approximately $900,000 from Hyundai Department Stores based in Seoul, Korea.

Chris Giordano, Premiere's Chairman, stated “This marks another milestone for our goal of bringing Western Fashion into SE Asia and Mainland China by first establishing our lines of clothing in Seoul, Korea which is the epicenter and harbinger for all that is fashion throughout all of Asia. Once our lines become established in Korea we will have tremendous impetus to move our clothing lines into Mainland China.”

Premiere Opportunities Group’s aim is to establish six to ten JVs over the next year with "Western Brand" clothing design manufacturers that do not have the required relationships to establish their brand and line in Southeast Asia and Mainland China.

Premiere Opportunities Group, Inc. (PPBL), closed Tuesday's trading session at $0.0057, even for the day, on 6,533,427 volume with 11 trades. The average volume for the last 60 days is 836,920 and the stock's 52-week low/high is $0.0006/$0.014.

KleanGas Energy Technologies, Inc. (KGET)

PennyStocks24, Pumps and Dumps, Mad Money Picks, Stock Shock and Awe, Penny Stock General, Fast Money Alerts, and Super Hero Stocks reported recently on KleanGas Energy Technologies, Inc. (KGET), and we highlight the Company, here at the QualityStocks Daily Newsletter.

KleanGas Energy Technologies, Inc. is a research and development (R&D) company whose dedication is to producing alternative clean technologies that promote energy efficiency throughout a wide array of applications. KleanGas engages in the R&D of oxy-hydrogen gas used as an emissions reduction enhancer and energy savings system - either as a standalone unit or as a supplement to an existing device. KleanGas is a progressive ongoing development company focusing on the production of clean burning energy and fuels derived from water (H20). KleanGas Energy Technologies lists on the OTCQB.

KleanGas Energy Technologies designs, develops, and markets varied technologies. These include Oxy-Hydrogen on-demand generators, Reverse Fuel Cells, solar to Hydrogen, Welding, Cutting and other products to deliver a clean gas that provides energy savings, emissions reductions, on diesel, natural gas applications or fuel cells. Their Oxy-Hydrogen generators significantly reduce emissions. They accomplish this while increasing fuel economy with an increase in horsepower at a lower cost. A small injection of oxy-hydrogen extends the life of the engine by burning off carbon residue and reducing the need for oil changes.

KleanGas Energy Technologies earlier announced that they acquired a worldwide exclusive patent pending Oxy-Hydrogen generator technology for all kinds of gas and diesel internal combustion engines. Company President, Mr. William Wylie, announced that KleanGas completed the acquisition for the worldwide exclusive license of the KleanGas Oxy-Hydrogen Generators from Company Founder Mr. Dennis Klein. The Patent Pending Technology will allow KleanGas Energy Technologies to manufacture the generator systems for use in most gasoline and diesel internal combustion engines.

In September, KleanGas Energy Technologies announced the Company’s Netherlands biomass processing Joint Venture (JV) project with Global Apollo KleanGas, Ltd. (GAK). KleanGas is a 30 percent owner of GAK and GAK is a 25 percent owner of the Netherlands JV. At present, the JV is raising capital to complete the project.

KleanGas Energy Technologies, Inc. (KGET), closed Tuesday's trading session at $0.0008, even for the day, on 2,105,000 volume with 7 trades. The average volume for the last 60 days is 14,100,014 and the stock's 52-week low/high is $0.0007/$0.10.

rVue Holdings, Inc. (RVUE)

Today we are reporting on rVue Holdings, Inc. (RVUE), here at the QualityStocks Daily Newsletter.

rVue Holdings, Inc. operates rVue, a demand-side platform (DSP) for planning, buying, and managing Digital Out of Home (DOOH) and place-based media advertising. An advertising technology enterprise, the Company provides an online, internet based DSP that connects advertisers and/or advertising agencies with third party DOOH media or networks. This allows the advertiser to create a targeted advertising campaign and media plan, and negotiate that media plan simultaneously with all the third-party networks selected. rVue Holdings has offices in Illinois and Florida.

rVue connects more than 900,000 digital screens across 210 networks delivering access to 250 million daily impressions in one straightforward platform. Through their strategic media services group, the Company executes complete campaigns on behalf of advertising clients or their agencies.

The rVue DSP is accessible through the Internet. Through rVue, once an advertising campaign has been agreed to between the advertiser and the DOOH network owner, the DOOH networks receive the display advertising to be shown on their installed base of digital media displays. rVue permits programming and advertising to undergo customization for display in specific venues, at specific times, and for demographic targeting.

The Company provides the tools for advertisers and advertising agencies to customize campaigns for details as specific as location, customer preference, product availability, current events, and other needs. rVue provides Proof- of-Play analytics and the network statistics required to monitor advertising on the networks and assist in evaluating the performance or refinements required for an advertising campaign, in some cases real time. In addition, the Company’s integrated analytics provide insight and opportunities for advertisers and agencies to extend the reach, impact, as well as engagement of future campaigns.

Recently, rVue announced that Mr. Thomas L. Harrison was appointed to the Board of Directors, effective September 19, 2013. Mr. Harrison is Chairman Emeritus of the Diversified Agency Services division of marketing communications holding company Omnicom Group, Inc. (OMC).

rVue Holdings, Inc. (RVUE), closed Tuesday's trading session at $0.20, up 43.88%, on 351,032 volume with 16 trades. The average volume for the last 60 days is 71,863 and the stock's 52-week low/high is $0.03/$0.32.

Aradigm Corp. (ARDM)

FeedBlitz reported previously on Aradigm Corp. (ARDM), and we are reporting on the Company today, here at the QualityStocks Daily Newsletter.

Aradigm Corp. is an emerging specialty pharmaceutical company whose shares trade on the OTCQB. The Company is focusing on the development and commercialization of a portfolio of drugs delivered by inhalation for the treatment of severe respiratory diseases. Aradigm has product candidates addressing the treatment of bronchiectasis, cystic fibrosis, inhalation tularemia and anthrax infections, and prevention of respiratory and other diseases in tobacco smokers through smoking cessation. Aradigm is based in Hayward, California

Aradigm is concentrating on the continued development of proprietary respiratory disease therapies. Their strategic plan also includes pursuing regulatory pathways that reduce the time, costs and risks associated with product development, and conservation of capital for proprietary product development by way of the outsourcing of late stage clinical and commercial scale manufacturing.

The Company’s strategy additionally includes the deployment of a specialized sales and marketing force to meet the distinct needs of pulmonologists and sub-specialists in America. In addition, their strategy includes out-licensing technology and intellectual property (IP) assets for applications that lie outside their strategic interests and core expertise.

Aradigm’s pipeline includes ARD-3150 Pulmaquin® and ARD-3100 Lipoquin®: Inhaled Ciprofloxacin for the Management of Infections in Non-Cystic Fibrosis Bronchiectasis (BE) Patients, and ARD-1600 (Nicotine) Tobacco Smoking Cessation Therapy. Their pipeline also includes ARD-1100 (Liposomal Ciprofloxacin).

Recently, Sigma-Tau PharmaSource, Inc. and Aradigm announced that they entered into a wide-ranging manufacturing services agreement. Sigma-Tau PharmaSource will provide Aradigm with clinical and commercial supplies of Pulmaquin®. Pulmaquin is Aradigm’s proprietary formulation of inhaled ciprofloxacin for the treatment of severe respiratory diseases, including non-cystic fibrosis bronchiectasis (BE).

With this agreement, Sigma-Tau PharmaSource will manufacture all product for Aradigm’s Phase 3 clinical studies. They will also support Aradigm in the preparation of their submissions to regulatory authorities in pursuit of marketing approval for the product. Sigma-Tau PharmaSource is a wholly owned subsidiary of Sigma-Tau Pharmaceuticals, Inc., a biopharmaceutical contract manufacturer specializing in complex injectable formulations, including liposomal drug delivery technology and PEGylation.

Aradigm Corp. (ARDM), closed Tuesday's trading session at $0.205, up 2.50%, on 742,657 volume with 53 trades. The average volume for the last 60 days is 80,003 and the stock's 52-week low/high is $0.09/$0.22.


The QualityStocks
Company Corner


CD International Enterprises, Inc. (CDII)

The QualityStocks Daily Newsletter would like to spotlight CD International Enterprises, Inc. (CDII). Today, CD International Enterprises, Inc. closed trading at $0.099, up 10.00%, on 913,279 volume with 106 trades. The stock’s average daily volume over the past 60 days is 77,172, and its 52-week low/high is $0.041/$0.205.

CD International Enterprises, Inc. today announced that Minera MAPSA S.A., a Peruvian mining and exploration company, has completed the formal transfer of title of all mining concessions for 178k acres of mining properties in southern Peru to CDII Minerales Peru SAC. With the completion of this transfer CD International's wholly owned subsidiary CDII Minerals and MAPSA each now own a 50% interest in CDII Peru on the property, which is divided into three project sites, the largest being the SAMA site, spanning approximately 128,000 acres.

CD International Enterprises, Inc. (CDII) is a U.S. based company that produces, sources, and distributes industrial commodities in China and the Americas, in addition to providing business and financial consulting services. Headquartered in Deerfield Beach, Florida, with corporate offices in Shanghai, CD International Enterprises’ unique infrastructure provides a platform to expand business opportunities globally.

Through its wholly owned subsidiary, International Magnesium Group, CD International Enterprises owns and operates one of the leading producers of magnesium in the world. International Magnesium Group sources its magnesium from six production facilities in the People's Republic of China, with a combined annual production and distribution capacity of approximately 80,000 metric tons of magnesium ingots and 10,000 metric tons of magnesium powder.

CD International Enterprises also sources, aggregates, and distributes iron ore, manganese ore, and scrap metals for companies located throughout the People’s Republic of China via wholly owned subsidiary CDII Minerals. The scope of CDII Minerals’ services include: purchasing, financing, logistics, quality control, in addition to conducting comprehensive legal, financial, and technical due diligence on suppliers.

The company’s management team possesses the necessary leadership expertise and a solid working knowledge of the unique characteristics of business operations in the U.S., China, Mexico, and South America. Employing a global growth strategy, CD International Enterprises has the unique ability to identify emerging market opportunities and provide comprehensive solutions or services relevant to conducting cross border business. Disclaimer

CD International Enterprises, Inc. Company Blog

CD International Enterprises, Inc. News:

Minera MAPSA Completes Transfer of 178,000 Acres of Mining Concessions in Peru to CD International Enterprises Subsidiary

Law Offices of Howard G. Smith Announces Investigation on Behalf of Shareholders of CD International Enterprises, Inc.

CD International Enterprises and Minera MAPSA S.A. Partner to Explore Iron Ore Mining, Distribution and Facilities Opportunities in Peru

Midwest Energy Emissions Corp. (MEEC)

The QualityStocks Daily Newsletter would like to spotlight Midwest Energy Emissions Corp. (MEEC). Today, Midwest Energy Emissions Corp. closed trading at $0.50, even with yesterday's close, on 2,500 volume with 1 trade. The stock’s average daily volume over the past 60 days is 10,820, and its 52-week low/high is $0.15/$1.30.

Midwest Energy Emissions Corp. announced today that the Company is a Partnering Sponsor of the University of North Dakota Energy & Environmental Research Center, Air Quality IX Conference (http://www.undeerc.org/aq9/), the nation's premier conference on emission control, this October 21-23, at the Crystal Gateway Marriott in Arlington, VA. Midwest Energy CEO Alan Kelley will serve as the Session Chair for a conference session entitled "Hg Control - Sorbent Injection," during which he will discuss mercury emission control with top industry experts and other conference attendees.

Midwest Energy Emissions Corp. (MEEC) develops and delivers patented, cost-effective mercury capture systems and technologies to power plants and other coal-burning units in the United States and Canada. As a result of the company’s innovative, patented mercury removal technologies, customers can attain compliance with new, highly restrictive government emissions regulations, in the most effective and economical manner.

In 2011, the EPA issued its Mercury and Air Toxics Standards (MATS) for power plants. The new rule is intended to reduce air emissions of heavy metals, including mercury (Hg), from all major U.S. power plants. It is projected that the total national cost of this mandate will reach $9.6 billion annually. More than a dozen states have established even more stringent emission limits, further increasing demand for energy emission control technology.

Leveraging its partnership with University of North Dakota’s Energy & Environment Research Center (EERC), the premier center of mercury control research, Midwest Energy Emissions is well positioned to meet and exceed new government regulations with its exclusive patent rights to EERC’s mercury control technology. The company’s customer-centric mercury capture solutions use a combination of materials tailored specifically to customers’ coal-fired units.

Years of research and testing with the EERC has enabled Midwest Energy to deliver one of the most effective low-cost and high-capture solutions possible – typically without impacting operations or requiring extensive capital equipment changes. The total mercury solution offered by Midwest Energy Emissions is uniquely formulated to optimize mercury capture at any coal-fired unit. Disclaimer

Midwest Energy Emissions Corp. Company Blog

Midwest Energy Emissions Corp. News:

Midwest Energy Emissions Corp. to Partake as Partnering Sponsor of the Energy and Environmental Research Center Air Quality IX Conference

Midwest Energy Emissions Corp. Engagement of QualityStocks Investor Relations Services

Midwest Energy Emissions Corp. to Present at the Southern California Investor Conference on Thursday, August 8, 2013

GlobalWise Investments, Inc. (GWIV)

The QualityStocks Daily Newsletter would like to spotlight GlobalWise Investments, Inc. (GWIV). Today, GlobalWise Investments, Inc. closed trading at $0.10, even for the day. The stock’s average daily volume over the past 60 days is 31,050, and its 52-week low/high is $0.05/$0.625.

GlobalWise Investments, Inc. today announced their participation in the 2013 OPRA Fall Conference to be held in Dublin, Ohio, October 8 - 9. OPRA is a statewide association of service providers whose mission is focused on Ohioans with developmental disabilities, consisting of more than 150 organizations, both for-profit and not-for-profit, providing services to more than 15k Ohioans with developmental disabilities.

GlobalWise Investments, Inc. (GWIV), via wholly-owned subsidiary Intellinetics, Inc., is a leading-edge technology company focused on Enterprise Content Management (ECM) solutions for the digital age. The ECM industry continues to grow rapidly as a result of unrestricted proliferation of digital content within today's business environment. Leveraging its proprietary cloud-based computing software, GlobalWise is poised to capture a significant market share of this burgeoning industry.

GlobalWise's ECM service is delivered to customers via five unique delivery models which cover the spectrum of business needs: Cloud/Saas (Software as a Service), Hardware Vendor Integrated Service, Software Vendor Integrated Service, Premise (Client-Server), Hybrid (Premise & Cloud/Saas).This diversity gives advanced security & privacy features with an on-demand structure needed for large Tier 3 and Tier 4 businesses that are currently underserved by the market.

The Intellinetics platform defines a new industry benchmark and game-changing approach by combining advanced virtualization & automated content management with an open and service-oriented architecture using web services. The company provides strategies, tactics, and technologies used to manage paper and digital assets from capture to long-term archive, without the need for manual processes conducted by a full time employee.

GlobalWise's management boasts a combined total of over 60 years in ECM leadership and industry experience. The ECM industry is expected to exceed $5.1 billion by 2013 with Gartner predicting a compound annual growth rate of 9.5%. IBM Market Insights predicts adoption of cloud computing to grow by 26% CAGR between 2010 through 2013. Leveraging management and key department heads, Intellinetics has a strong foundation from which to capture significant market share within the lucrative $149 billion Business Software & Services industry. Disclaimer

GlobalWise Investments Company Blog

GlobalWise Investments News:

GlobalWise to Participate at the 2013 OPRA Fall Conference

GlobalWise to Participate at the 2013 ANCOR Technology Summit & Showcase

GlobalWise Investments Announces Appointment of a New Board Member

Epazz Inc. (EPAZ)

The QualityStocks Daily Newsletter would like to spotlight Epazz Inc. (EPAZ). Today, Epazz Inc. closed trading at $0.0008, off by 11.11%, on 4,792,000 volume with 23 trades. The stock’s average daily volume over the past 60 days is 14,164,603 and its 52-week low/high is $0.0006/$0.0099.

Epazz, Inc. today provided an investor update in regards to ongoing revenue growth and the spin-off project currently underway, as revenues for fiscal 2012 totaled $1,193,217, a tenfold increase compared to when the Company first began publicly trading just a few years ago. The Company's sales continue to grow at record-setting levels and they were happy to provide a comprehensive update and explanation of the spin-off process to markets as well today.

Epazz Inc. (EPAZ) is a leading cloud-based software company focused on providing customized cloud applications to Fortune 500 enterprises, government agencies, and higher education institutions. Targeting a strong growth industry, the company is rapidly expanding via strategic acquisitions, a full suite of in-house products and services, and diversified streams of income.

The fully reporting company is demonstrating substantial performance in a competitive industry, completing six acquisitions while maintaining organic subsidiary growth. In the last three years, Epazz revenues have increased by more than 300%. The company will produce its first spinoff with “Project Flex” and issue a stock dividend to shareholders of record on the record date.

As an enterprise-wide software company, Epazz is adeptly serving the increasing information technology demand of the 21st century. According to IDC, the premiere global market intelligence firm, the IT cloud services industry is expected to grow from $40 billion to $100 billion in just four years. Management anticipates the company’s growth to accelerate as the market for its technology solutions continues to expand.

Epazz BoxesOS™ v3.0 is the complete business web-based software package for small to mid-size businesses, Fortune 500 enterprises, government agencies, and higher education institutions. The turnkey enterprise system, which includes content, integration, customization, and marketing services, provides many of the web-based applications organizations would have to otherwise buy separately. Disclaimer

Epazz Inc. Blog

Epazz Inc. News:

Epazz Revenues Increase Over 1,000 Percent Since Going Public

Epazz's Short Interest in Market Climbs; Short Interest in Excess of 47 Percent of Total Volume for Sep 2013

Epazz Transitioning Into a Holding Company via Acquisitions & Spin-offs Business Model Update

International Stem Cell Corp. (ISCO)

The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.173, up 14.57%, on 4,578,069 volume with 438 trades. The stock’s average daily volume over the past 60 days is 590,540, and its 52-week low/high is $0.13/$0.41.

International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. The company was first to perfect the natural phenomenon of parthenogenesis, which utilizes unfertilized human eggs to create hpSCs. These stem cells, created in a particular form called HLA homozygous, can be immune-matched to millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.

hpSCs are as pluripotent as embryonic stem cells (ESCs) and have significant therapeutic potential but their creation does not involve the destruction of a viable human embryo – thus sidestepping the controversy and ethical dilemmas associated with the use of human embryonic stem cells. Different from induced pluripotent stem cells (iPSs), hpSCs do not involve manipulation of gene expression back to a less differentiated stage – a practice that may become a safety or regulatory obstacle in clinical applications.

A relatively small number of hpSC lines can offer the potential of producing the first true stem cell bank, UniStemCell, which ISCO intends to create as a means of serving populations across the globe. The company's scientists are currently focused on using hpSC to treat severe diseases of the eye, nervous system, and liver, for which cell therapy has been clinically proven but is limited due to the unavailability of safe human cells.

In addition to its therapeutic focus, ISCO also provides two revenue streams. Firstly through its subsidiary Lifeline Cell Technology, specialized cells and growth media for biological research around the world, and secondly its subsidiary Lifeline Skin Care, the company manufactures and sells anti-aging skincare products utilizing an extract from the hpSC and by leveraging the latest discoveries in the fields of stem cell biology, nanotechnology, and skin cream formulation technology. Disclaimer

International Stem Cell Corp. Company Blog

International Stem Cell Corp. News:

International Stem Cell Corporation to Present at 12th Annual BIO Investor Forum October 8-9th, 2013

International Stem Cell Corporation to Present New Data From Parkinson's Disease Program at the American Neurological Association 2013 Annual Meeting

International Stem Cell Corporation Advances Parkinson's Disease Program Towards IND Stage

Advaxis, Inc. (ADXS)

The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $4.95, up 9.27%, on 47,067 volume with 102 trades. The stock’s average daily volume over the past 60 days is 32,500, and its 52-week low/high is $2.60/$19.375.

Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.

The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.

Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.

The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer

Advaxis, Inc. Company Blog

Advaxis, Inc. News:

Advaxis Lead Product Candidate ADXS-HPV in Combination with PD-1 Antibody Significantly Improves Immune and Therapeutic Efficacy in Preclinical Study

Advaxis Announces Three Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer Annual Meeting

Advaxis Appoints Daniel J. O'Connor President and CEO and Elects Dr. James Patton Non-Executive Chairman of the Board

Sohm, Inc. (SHMN)

The QualityStocks Daily Newsletter would like to spotlight Sohm, Inc. (SHMN). Today, Sohm, Inc. closed trading at $0.006, up 22.45%, on 709,000 volume with 6 trades. The stock’s average daily volume over the past 60 days is 214,907, and its 52-week low/high is $0.0027/$0.013.

Sohm, Inc. (SHMN) is a globally recognized pharmaceutical manufacturer that develops, manufactures, and distributes generic, private label, and Sohm-innovated pharmaceutical, cosmeceutical, and nutraceutical products. The company exports product worldwide, with a focus on distribution in emerging markets such as Africa, Latin America, and Southeast Asia.

In 2012, Sohm was voted the fastest growing generics prescription drug manufacturer at the 30th All India Conference of National Integrated Medical Association. Committed to being a global leader in improving the health and quality of people’s lives in every corner of the world, the company has U.S. headquarters in Buena Park, CA, with international headquarters located in Ahmedabad, India, and several corporate offices located within the UK and China.

Research and development activities capitalize on the company’s expertise in numerous drug delivery technologies, including solid dosage form, oral-controlled and sustained releases semi-solid, liquid, oral transmucosal, transdermal, gel, injectable, and other drug delivery technologies, as well as the application of these technologies to proprietary drug forms.

To ensure regulatory compliance, the company continuously assesses and monitors the output of the existing quality systems, and application of evolving industry guidelines and regulations. Leveraging a global presence, an expanding drug portfolio that covers all major treatment categories, and a respected brand, Sohm is well positioned to continue its rapid growth.. Disclaimer

Sohm, Inc. Company Blog

Sohm, Inc. News:

SOHM, Inc. Announces Engagement of QualityStocks Investor Relations Services

SOHM Launches a Unique Protein Supplement First Time in India

SOHM Announces First Quarter 2013 Financial Results

Raptor Resources Holdings Inc. (RRHI)

The QualityStocks Daily Newsletter would like to spotlight Raptor Resources Holdings Inc. (RRHI). Today, Raptor Resources Holdings Inc. closed trading at $0.022, up 10.00%, on 275,400 volume with 6 trades. The stock’s average daily volume over the past 60 days is 144,788, and its 52-week low/high is $0.0002/$0.0395.

Raptor Resources Holdings Inc. (RRHI) is a publicly traded holdings company focused on mineral resource acquisition, exploration, and development. The company currently has two subsidiaries: Mabwe Minerals Inc. (MBMI), a natural resources and hard asset company engaged in the mining and commercial sales of industrial minerals & metals with first focus on barite; and TAG Minerals Inc., a mineral & metal resource acquisition, exploration, and development company with first focus on alluvial surface gold.

Mabwe Minerals has been the focus of the parent company’s efforts the last two years to move into commercial barite production. RRHI shareholders share a common interest with MBMI shareholders in the success of Dodge Mine as the parent company owns 90M shares of MBMI. The Dodge Mine property consists of three hydrothermal mountains representing 123 hectares containing multiple deposits of superior-grade barite, limestone, and talc.

TAG Minerals, along with its indigenous affiliate, TAG Minerals Zimbabwe (Private) Limited, is responsible for alluvial gold production along with the development of greenfield assets targeting bedrock gold and other potential metals & minerals. As MBMI is transitioning into commercial barite production, RRHI will now focus on building assets within TAG Minerals with the intent of moving into commercial production within the next 18 months. TAG Minerals will utilize the latest in Heavy Particle Concentrators (HPC-30/HPC-100) through its relationship with Extrac-TEC whose gold recovery and mineral separation technology captures up to 98% of alluvial gold down to 50 microns. The company is in early stage exploration evaluating potential alluvial sites to ensure they meet the company's criteria for commercial production. Coupled with MBMI's acquisition of WGB Kinsey & Company, TAG Minerals is well positioned to fast track into commercial production once the company has successfully completed its exploratory testing.

RRHI management continues to improve its balance sheet as reflected in the company's SEC 10k filing, including favorable reductions in the company's debt/liabilities and securing 54.4M shares and 14.4M warrants of RRHI from prior employees. The company is committed to growing its asset base in TAG Minerals moving forward. Disclaimer

Raptor Resources Holdings Inc. Company Blog

Raptor Resources Holdings Inc. News:

Mabwe Minerals Launches New Web Site as Affiliate Finalizes Barite Specification Sheets to Commence Barite Qualification

Mabwe Minerals Commences Mining Operations at Dodge Mine

Mabwe Minerals Frames Strategic Alliances With Steinbock Minerals Ltd. and Yasheya Ltd.


Rate Us
Tell us how we're doing!
Click here to begin your review.

Today's Top 3
Investment Newsletters



Real Pennies




The Stock Wrangler

By The Numbers Charts

The QualityStocks Public Company Sponsor News

Featured Sponsor

Daily Sponsors


The QualityStocks By The Numbers Report

Click the chart below to see the full report

About "The QualityStocks Daily"

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market
each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge"
based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?

We Want To bring our subscribers the top movers in an unbiased setting.

“Homework Eliminates Mistakes"

Please never invest in a company anyone profiles unless you do the proper research and due diligence.
QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.
Please consult the QualityStocks Market Basics Section on our site.


About Us     Archives     Blog     Clients     Disclaimer     Market Basics    Partners      Quotes & News     Video     Contact Us

twitter icon facebook icon

QualityStocks Logo

Copyright © 2006 - 2012. QualityStocks 3370 N. Hayden Rd., Suite 123-591, Scottsdale, AZ 85251